Article Text

Download PDFPDF
Highlights from the literature

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

New treatment for Tourette's

Tics are common and may present to both paediatric and child psychiatry clinics. For most, reassurance and advice are all that is needed, but for a few they can become seriously disabling and may progress to Tourette's syndrome. Treatment with antipsychotic drugs such as Haloperidol is effective, but can severe side-effects such as sedation, dystonia and tardive dyskinesia. Newer ‘atypical’ antipsychotic drugs are being used increasingly in schizophrenia as they appear to be better tolerated. One such is Aripiprazole: researchers from Jiangsu, China set out to review the literature on its use in Tourette's in young people, and attempt a meta-analysis (Liu Y, et al. J Child and Adolescent Psychopharmacology 2016. doi:10.1089/cap.2015.0125).

They found 10 studies, but only one was a randomised controlled trial (RCT); the others were open trials. All used one of two standardised scoring systems: Yale Global Tic Severity Score (YGTSS) or Clinical Global Impressions Scale for Tic Severity (CGI-S). Over 300 young people (mean age 11.6 years) were involved.

All the studies showed a significant improvement (overall effect size for fall in YGTSS −2.0 [95% CI …

View Full Text